Abiraterone
The question
To ask the Secretary of State for Health and Social Care, whether the NICE guidance on abiraterone produced in 2021 was based on abiraterone's cost in generic form.
Answered by Dr Zubir Ahmed
The National Institute for Health and Care Excellence’s (NICE) published guidance on abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, which has the reference code TA721, was developed before the patent for abiraterone expired and was therefore based on the cost of the branded medicine.
NICE is now re-evaluating abiraterone, both the originator and the generics, for the treatment of newly diagnosed high-risk hormone-sensitive metastatic prostate cancer and currently expects to publish the final guidance on 19 November 2025. The progress of this guidance can be followed at the following link:
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →